C5a Neutralization by Clinical-Stage AON-D21 Shows Promise in Animal Models from Pneumonia to Lung Cancer

Time: 2:00 pm
day: Day Two


  • AON-D21 is a mirror-image (L-)RNA aptamer that binds C5a and inhibits its signaling on C5aR1 and C5aR2
  • Analyze preclinical data showing that C5a-inhibition with AON-D21 is efficacious in diseases such as pneumonia, sepsis and lung cancer
  • AON-D21 has passed Phase 1 First in Human studies and will enter a Phase 2 Proof of Concept trial shortly